3,000+ Patient Meta-Analysis Reinforces Importance of Platelet Reactivity Testing to Aid in Risk Assessment
10/27/2011 12:14:19 PM
SAN DIEGO--(BUSINESS WIRE)--Accumetrics, Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced that results from a patient-level meta-analysis of more than 3,000 stent patients have been published in the Journal of the American College of Cardiology1. Patients in the study with high platelet reactivity, as measured by the Accumetrics’ VerifyNow P2Y12 Test, exhibited more than twice the rate of cardiovascular death, heart attack and stent thrombosis over 2 years compared to patients without high platelet reactivity. The VerifyNow P2Y12 Test is used to measure a patient’s platelet reactivity and the antiplatelet effect of medications such as clopidogrel and prasugrel (Plavix® and Effient®).